Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Nanobiotix
Incyte Corporation
Eli Lilly and Company
Tempest Therapeutics
Fate Therapeutics
Nektar Therapeutics
Nektar Therapeutics
Jules Bordet Institute
Incyte Corporation
Duke University
Sheba Medical Center
MultiVir, Inc.